Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
about
Tumor angiogenesis: pericytes and maturation are not to be ignoredBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesExosomes-mediate microRNAs transfer in breast cancer chemoresistance regulationPlants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggabilityModulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1A case of HER2-positive male occult breast carcinoma with skin and lymph node metastases that exhibited complete response to trastuzumab monotherapyInvestigation of Prognostic Factors and Survival without Recurrence in Patients with Breast Cancer.Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.Bioengineering embryonic stem cell microenvironments for the study of breast cancerMolecular approaches to personalizing management of ovarian cancer.Finding a place for genomics in health disparities research.Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancerManagement of patients with metastatic breast cancer.Design and evaluation of radiolabeled tracers for tumor imaging.Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer.The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma.EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Analysis of clinicopathological factors associated with bone metastasis in breast cancer.
P2860
Q21296683-9A1549FA-AD21-4AAB-ADB1-644DD63A917EQ26783705-E10D5B41-4EDE-4E45-B6EF-0947F5EE82C8Q28066991-FC12E323-2C13-4E1C-BE17-664751D1622DQ28385642-4C65A4AC-0F93-41E0-8E67-34EEC7BCABB1Q28655621-732EE4B6-8A1D-4FF2-A6AA-174ECB14A003Q33625763-E2810A8E-2370-4094-B28D-FC0A98572A67Q33630737-DF22E645-8E1C-43DC-83BD-AC6C4EC46AEEQ34278253-58013152-21B6-40CB-84D5-3064A7E0D590Q34454213-4259B12C-2770-4048-8705-56AB82C49092Q34988368-C4691418-3A75-4A0A-9500-D19E5BFE4053Q35600151-F1A2EA13-E6E8-4B75-81F0-A8DE0A0F917FQ35760160-97043800-A49E-4E7A-AA09-ADA49B701DD2Q36936308-55EFC459-B5AA-4299-BF9A-CC6D4B794C6DQ36958226-F96ADA96-86D5-4B6C-BFE5-1115F6EF82E8Q37355762-33F2A326-8194-4CF0-B16C-0AB9AA4D59E0Q37933166-BD4DBCDA-3C73-4EA9-92A9-01D6C92052D0Q38137253-CD61A731-C7CA-43E6-B6E0-71BF77DC89B8Q40105271-AE44442A-B200-438F-8775-64E1D06F586EQ41972324-B0C292FC-F81C-4BCB-838E-D7EBA27FF63AQ43191053-EBEB772E-7EF1-4D83-BA62-762DFCE193ABQ48102534-36E5E085-1C7D-4114-90E9-4A21756E1155Q54451157-49582FEE-43FF-4035-9647-B8F31B145CC1
P2860
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Human epidermal growth factor ...... vanced, and recurrent disease.
@ast
Human epidermal growth factor ...... vanced, and recurrent disease.
@en
type
label
Human epidermal growth factor ...... vanced, and recurrent disease.
@ast
Human epidermal growth factor ...... vanced, and recurrent disease.
@en
prefLabel
Human epidermal growth factor ...... vanced, and recurrent disease.
@ast
Human epidermal growth factor ...... vanced, and recurrent disease.
@en
P2860
P1476
Human epidermal growth factor ...... vanced, and recurrent disease.
@en
P2093
Rena Callahan
Sara Hurvitz
P2860
P356
10.1097/GCO.0B013E3283414E87
P577
2011-02-01T00:00:00Z